Product
Autologous NY-ESO-1-specific CD8-positive T Lymphocytes
2 clinical trials
15 indications
Indication
Platinum-Resistant Ovarian CarcinomaIndication
Fallopian Tube CarcinomaIndication
Platinum-Sensitive Ovarian CarcinomaIndication
Recurrent Fallopian Tube CarcinomaIndication
Recurrent Ovarian CarcinomaIndication
Recurrent Primary Peritoneal CarcinomaIndication
Ovarian CancerIndication
Primary Peritoneal CarcinomaIndication
HLA-A*0201 Positive Cells PresentIndication
NY-ESO-1 Positive Tumor Cells PresentIndication
Recurrent Myxoid LiposarcomaIndication
Synovial SarcomaClinical trial
A Phase I, Open Label Study Evaluating the Safety and Efficacy of Adoptive Transfer of Autologous NY-ESO-1 CD8-TCR Engineered T Cells and NY-ESO-1 CD4-TCR Engineered Hematopoietic Stem Cells (HSC) After a Myeloablative Conditioning Regimen, With Administration of IL-2 in Patients With Recurrent or Treatment Refractory Ovarian, Fallopian Tube or Primary Peritoneal CancerStatus: Active (not recruiting), Estimated PCD: 2021-01-30
Clinical trial
Phase I Study of Cellular Adoptive Immunotherapy Using Autologous CD8+ NYESO-1-Specific T Cells and the NY-ESO-1 Immunostimulatory Agents LV305 or CMB305 for Patients With SarcomaStatus: Completed, Estimated PCD: 2022-12-06